BioSpace News Archive

SHR0302 monotherapy achieved positive results on reaching primary endpoints with statistical significance, delivering significant improvements in skin clearance Both doses were shown to be superior to placebo for key secondary endpoints AEs were manageable and generally transient and reversible Efficacy and safety profile support continued advancement in moderate-to-

Liberty Health Sciences Inc. (CSE: LHS) (OTCQX: LHSIF) www.libertyhealthsciences.com (“Liberty” or the “Company”), a provider of high-quality cannabis, announced today that it is offering all holders of 12% Senior Secured Convertible Debentures (the “Debentureholders”) a 12-month extension to the original November 22, 2020 maturity date (the “Extension Option”) that were originally issued on November 22, 2017 (the “Debentures”).

HiFiBiO Therapeutics , a multinational biotherapeutics company with unique expertise in immune modulation and single-cell science, today announced the successful completion of the first cohort of the Phase I study ( NCT04590430 ) of HFB30132A, a SARS-CoV-2 neutralizing antibody for the treatment and prevent

PerkinElmer, Inc. (NYSE: PKI) announced today that its PKamp™ Respiratory SARS-CoV-2 RT-PCR Panel has received clearance to be marketed as an in vitro diagnostic (IVD) device in more than 30 countries by meeting the requirements of the European In Vitro Diagnostic Directive (IVDD). This test is currently under review b

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced that it has been issued U.S. patent number 10815271 (application number 16/311,593) from the United States Patent and Trademark Office (USPTO) covering the composition of matter for SLS-007,

Greenphire, the global leader in financial lifecycle management for clinical trials, says patient enrollment for global clinical trials has returned to pre-COVID levels.

Data highlight the importance of early intervention with fast-acting E-selectin inhibitors to disrupt the underlying inflammatory mechanisms driving acute vaso-occlusive crisis (VOC) - Abstracts for two of GlycoMimetics’ wholly-owned product candidates, rivipansel and GMI-1687, accepted for poster and oral presentations ROCKVILLE, Md.--( BUSINESS WIRE )-- GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that new post hoc analyses of the

Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology based therapies for prevalent inflammatory conditions, announced today that the Company will present at the 2020 MedTech Innovation Forum hosted by Roth Capital Partners on Wednesday, October 28, 2020.

Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced upcoming presentations at conferences and medical meetings: Investor Conference: Event: Stifel 2020 Annual Healthcare Conference Date: November 17, 2020, 4:40 pm ET Medical and Scientific Meetings: Event: Macrophage-dir

NICCI is Getinge’s latest innovation in Advanced Hemodynamic Monitoring, providing continuous and noninvasive hemodynamic insights to reduce the risk of severe complications for patients with low blood pressure